Raritan, NJ (July 1, 2011) - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral ...

To receive coverage for Xarelto, a person must be enrolled in a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) plan that includes prescription drug coverage. This article ...

Providing validation to what many physicians are already doing, a new study suggests that non-vitamin K antagonist oral anticoagulants (NOACs)—rivaroxaban, in particular—are effective alternatives to ...

Bayer has launched a trial of its anticoagulant Xarelto in long-term, secondary prevention of blood clots. The EINSTEIN CHOICE study will investigate Xarelto (rivaroxaban) 10 mg and 20 mg once daily ...

Next-gen anticoagulant leader Xarelto from Johnson & Johnson and Bayer has fierce competition breathing down its neck. But now, the team has some positive trial results in hand that could help bolster ...

Johnson & Johnson’s JNJ subsidiary, Janssen Pharmaceuticals announced that it has submitted a new drug application (NDA) for its blood thinner drug, Xarelto (rivaroxaban), seeking approval to treat ...

Bayer has said a failed trial for a potential new use of anticoagulant Xarelto will not affect forecast peak sales of $5 billion – although it will not help it gain ground on Bristol-Myers Squibb’s ...

XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...